Thus, our findings significantly enhance the understanding of CoREST inhibitor efficacy in combination with RA treatment, revealing new therapeutic avenues for a broader subset of AML patients beyond those traditionally responsive to retinoids. The gene discussed is RCOR1; the disease is acute myeloid leukemia.